Neuroscientific Biopharmaceuticals
NSBPerth, Australia· Est.
Australian MSC biotech advancing StemSmart™ therapy for Crohn’s disease and other inflammatory disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian MSC biotech advancing StemSmart™ therapy for Crohn’s disease and other inflammatory disorders.
ImmunologyInflammatory Bowel Disease
Technology Platform
StemSmart™ is a patented GMP‑grade manufacturing process that isolates and primes mesenchymal stem cells for enhanced anti‑inflammatory activity.
Opportunities
Regulatory approval for Crohn's disease could unlock a sizable market, while expansion into lung and kidney indications broadens the addressable patient base.
Risk Factors
Clinical efficacy uncertainty, manufacturing scale‑up challenges, and competition from larger MSC developers may impede commercialization.
Competitive Landscape
Key competitors include Mesoblast, TiGenix/Takeda, and Pluristem; Neuroscientific differentiates through its patented StemSmart™ priming technology and focused Australian manufacturing footprint.